Given Imaging (GIVN) Updates on PillCam COLON 2 Enrollment, Ingestion
Up)
Given Imaging (Nasdaq: GIVN), has announced that approximately 700 patients have been enrolled in the Company's PillCam COLON 2 pivotal trial, and more than 500 patients have ingested PillCam COLON 2 in the trial.
In total, seventeen sites will enroll more than 800 patients in the trial, aged 50-75 years, who are at average risk for colonic polyps and comprise the normal screening population. The results will support the Company's 510k submission to the U.S. Food and Drug Administration (FDA).
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
In total, seventeen sites will enroll more than 800 patients in the trial, aged 50-75 years, who are at average risk for colonic polyps and comprise the normal screening population. The results will support the Company's 510k submission to the U.S. Food and Drug Administration (FDA).
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Perrigo (PRGO) Gets FDA Approval for Generic Gynazole 1
- Repros Therapeutics (RPRX) Modifies Pivotal Androxal Protocol
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
